Sunitinib for Two Cancers
The FDA has approved sunitinib (Sutent, Pfizer), a targeted treatment for patients with advanced kidney cancer and gastrointestinal stromal tumors (GISTs), a rare stomach cancer. This action marks the first time that the agency has approved an oncology product for two indications simultaneously. Sunitinib, a tyrosine kinase inhibitor, deprives tumor cells of blood and nutrients [...]
Read User's Comments